iwCLL 2021 | The latest on targeted therapies in CLL
Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, shares the latest updates on targeted therapies in chronic lymphocytic leukemia (CLL), including those that target Bruton’s tyrosine kinase (BTK), phosphoinositide 3-kinase (PI3K), and B-cell lymphoma 2 (BCL-2). Dr Eichhorst explains that first-generation targeted therapies had been partly neglected due to the toxicities associated with their use, such as the incidence of diarrhea associated with PI3K inhibitors; however, Dr Eichhorst reports that second-generation agents seek to address the issue of toxicity and offer a far more favorable safety profile. This interview took place at the 19th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held virtually in 2021.
Disclosures
Barbara Eichhorst, MD, has participated in consultancy and/or advisory boards with Janssen, Roche, Novartis, AbbVie, Gilead, Celgene, ArQule, AstraZeneca, Oxford Biomedica (UK), MSD and Miltenyi; has received speaker’s bureau from Janssen, Gilead, Roche, AbbVie, Novartis, Celgene, AstraZeneca, Adaptive Biotechnologies and Hexal; has received research funding from Janssen, Gilead, Roche, AbbVie, BeiGene and Astra Zeneca; and ha received travel, accommodation and/or expenses from Janssen, Roche, Novartis, AbbVie, Gilead and Celgene.
